Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Evaluate Vantage Homepage
  3. Topics
  4. Therapeutic Focus
  5. Central Nervous System

Central Nervous System

Thumbnail
May 05, 2022

Jazz overture rekindles hopes for orexin agonism

Thumbnail
May 05, 2022

Amyloid testing reaches a limited market

Article image
Vantage logo
May 03, 2022

Biogen says goodbye to Vounatsos and remaining Aduhelm hopes

The company's chief executive pays for the Aduhelm fiasco, but who will want to step up and take on the Biogen challenge?

Article image
Vantage logo
April 29, 2022

Go or no go? Lilly’s valuable diabetes contender

Tirzepatide heads for its first FDA approval and Enhertu eyes an earlier setting, as Verrica and Axsome keep their fingers crossed.

Article image
Vantage logo
April 26, 2022

Late-stage pain pipeline refuses to swell

Setbacks from Eliem, Ampio and Acadia thin an already sparse pain pipeline, which remains lacking in serious interest from big developers.

Article image
Vantage logo
April 25, 2022

A second trip-up makes Axsome look careless

Article image
Vantage logo
April 08, 2022

It’s official: expect near-zero Aduhelm sales for the foreseeable future

Aduhelm’s status as a commercial nonentity is confirmed, but what does the final coverage decision mean for follow-on amyloid-beta MAbs?

Article image
Vantage logo
April 07, 2022

Flotations tank in the first quarter

A correction – as long as it is not too severe – might not be a bad thing for the sector.

Article image
Vantage logo
April 07, 2022

Aptinyx discovers the perils of the data dredge

Article image
Vantage logo
April 01, 2022

Go or no go? Bristol's first-in-class hopes

April should mark the approval of some of the biggest drugs of 2022, including Alnylam's vutrisiran, while TG will hope to be spared pain at the PI3K adcom.

Article image
Vantage logo
March 31, 2022

Significant readouts for small players

Praxis and Relmada target depression as Athira and Taurx tackle Alzheimer’s.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

April 20, 2022

Genetic Medicine: The Next Generation

March 18, 2022

PD(L)anner - March 2022

View more...

Editor's Picks

Vantage logo
May 05, 2022

Bristol needs to get fresh

Vantage logo
May 04, 2022

The next generation of diabetes technology

Vantage logo
April 25, 2022

Nkarta: at least as good as Fate, at a tenth of the price

Vantage logo
April 26, 2022

How Gal appointment could influence strategy at Novartis

Vantage logo
May 01, 2020

US FDA approval tracker: April

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.